Where we at?, page-442

I am resigned to waiting on $ relevant announcements.
Just for the record the dosage issue has been on my mind for more than 2 1/2 years. Failure to nail it has been partly responsible for the price fall since about then then Bell Pottter wrote a report with a >$3.00 tag. Much of the rest of the price fall has been due to inept management both project and capital.

If the FDA come back and wants more on safety or anything else, then i think that is necessary to do something to raise the share price with the November option price cutoff looming.
They could do a deal on MPS to get through any FDA required add-ons. It has to be ready to go, now.
PAR could still go to type 2 ADR to enlarge the new investor pool, and run a promotion with US investors. That is what I would do at a cost of $7m or so, and do a deal on MPS. That is risky but not getting to 75c by Nov is IMO a worst case scenario.

Is the PAR board smart enough to see that, or are they just hoping and hoping knowing they have no answers?

I sympathize with all LTH. The only thing that matters is today's price in relation to the potential of PAR and others.
I suggest posters here call on the Board through Simon White to demonstrate on the day that FDA get back that they already have a thought through plan.
IMO. DYOR